Business
Aeterna Zentaris Reports Second Quarter 2011 Financial and Operating Results
All amounts are in U.S. dollars (except for share data). QUEBEC CITY, Aug. 10, 2011 /CN...
About this update from Cosciens Biopharma Inc.
[{"type":"text","content":"\n\n\n\n\n\nAll amounts are in U.S. dollars (except for share data).\n\n\nQUEBEC CITY, Aug. 10, 2011 /CNW Telbec/ - Aeterna Zentaris Inc.\n (NASDAQ: AEZS) (TSX: AEZ) (the \"Company\"), a late-stage drug\n development company specialized in oncology and endocrine therapy,\n today reported financial and operating results for the quarter ended\n June 30, 2011.\n\n\nSecond Quarter 2011 Highlights\n\n\nPerifosine\n\n\nApril 4, 2011: The Company announced that two posters on perifosine were\n presented at the 102nd annual meeting of the American Association for Cancer Research (\"AACR\")\n held in Orlando, Florida. The first poster illustrated perifosine's\n antitumor activity in a variety of gastric cell lines, and also\n enhanced the antitumor activity of 5-FU in parts of the cell lines -\n including 5-FU resistant cell lines. The second poster demonstrated\n that perifosine markedly enhanced the antitumor activity of the\n cellular TRAIL-based treatment and was able to overcome TRAIL\n resistance both in vitro and in vivo.\n\n\nSubsequent to quarter-end, on July 26, 2011, the Company announced the\n completion of patient recruitment for the ongoing Phase 3 trial with\n perifosine in refractory advanced colorectal cancer. The trial,\n involving over 430 patients, is being conducted pursuant to a Special\n Protocol Assessment (\"SPA\") with the Food and Drug Administration\n (\"FDA\") and with Fast Track designation.\n\n\nSubsequent to quarter-end, on July 12, 2011, the European Patent Office\n granted a patent for the use of alkyl phosphocholines, and, more\n specifically for perifosine, in the preparation of a medicament for the\n treatment of benign and malignant tumors, prior to and/or during the\n treatment with approved antitumor antimetabolites including 5-FU\n (\"fluorouracil\") and capecitabine. This patent will expire on July 28,\n 2023.\n\n\nAEZS-108\n\n\nParallel Scientific Advice process granted by and initiated with the FDA\n and EMA, with the aim to have the pivotal program in endometrial cancer\n defined by year-end.\n\n\nProgression of ongoing Phase 1/2 studies in castration refractory\n prostate cancer and in refractory bladder cancer.\n\n\nAEZS-130\n\n\nSubsequent to quarter-end, on July 27, 2011, the Company announced the\n completion of the Phase 3 trial with AEZS-130 as an oral diagnostic\n test f...